Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Jul 22, 2020

SELL
$72.01 - $120.39 $105,638 - $176,612
-1,467 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$69.78 - $116.21 $102,367 - $170,480
1,467 New
1,467 $113,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Banque Cantonale Vaudoise Portfolio

Follow Banque Cantonale Vaudoise and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Banque Cantonale Vaudoise, based on Form 13F filings with the SEC.

News

Stay updated on Banque Cantonale Vaudoise with notifications on news.